Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 11, 3441-3448
eCollection

Bioequivalence Study of Two Formulations of Flupirtine Maleate Capsules in Healthy Male Chinese Volunteers Under Fasting and Fed Conditions

Affiliations
Randomized Controlled Trial

Bioequivalence Study of Two Formulations of Flupirtine Maleate Capsules in Healthy Male Chinese Volunteers Under Fasting and Fed Conditions

Yanfang Liu et al. Drug Des Devel Ther.

Abstract

Aim: This study developed a high-performance liquid chromatography-tandem mass spectrometry method to simultaneously determine the concentrations of flupirtine and its major active metabolite D-13223 in human plasma in order to assess the bioequivalence (BE) of two flupirtine maleate capsules among healthy male Chinese volunteers under fasting and fed conditions.

Materials and methods: There were two single-center, randomized, single-dose, open-label, laboratory-blinded, two-period, cross-over studies which included 24 healthy male Chinese volunteers under fasting and fed conditions, respectively. Plasma samples were collected prior to and up to 48 h after dosing. The concentrations of flupirtine and its major active metabolite D-13223 in plasma samples were determined by a validated method, that is, high-performance liquid chromatography coupled with a tandem mass spectrometry detector. Pharmacokinetic metrics of area from time zero to the last measurable concentration (AUC0-t), area under the plasma concentration-time curve from administration to infinite time (AUC0-∞), and Cmax were used for BE assessment.

Results: Forty-eight healthy volunteers who met the criteria were enrolled and completed the study. According to the observation of vital signs and laboratory measurement, no volunteers had any adverse reactions. Under fasting condition, the geometric mean ratios (90% CI) of the test/reference drug for flupirtine were 103.0% (98.1%-108.2%) for AUC0-t, 102.9% (98.2%-107.9%) for AUC0-∞, and 97.0% (85.9%-109.5%) for Cmax. Under fed condition, the geometric mean ratios (90% CI) of the test/reference drug for flupirtine were 101.7% (98.4%-105.1%) for AUC0-t, 101.6% (98.5%-104.8%) for AUC0-∞, and 103.5% (94.7%-113.0%) for Cmax. The difference between test and reference formulations, Tmax, was not statistically significant. The 90% CIs of the test/reference AUC ratio and Cmax ratio of D-13223 were also within the acceptance range for BE both under fasting and fed conditions.

Conclusion: The two formulations of flupirtine maleate capsule were bioequivalent (the test and the reference products) under fasting and fed conditions, and thus both can be used interchangeably in the clinical setting.

Keywords: D-13223; LC-MS/MS; flupirtine.

Conflict of interest statement

Disclosure The authors report no conflicts of interests in this work.

Figures

Figure 1
Figure 1
Flupirtine (A) and d-13223 (B).
Figure 2
Figure 2
Mean plasma concentration–time profiles of flupirtine and D-13223 under fasting (A) and fed (B) conditions after an oral dose of 100 mg test capsule and reference capsule. Note: Each profile represents the mean + SD of 24 volunteers.

Similar articles

See all similar articles

References

    1. Klinger F, Geier P, Dorostkar MM, et al. Concomitant facilitation of GABA(A) receptors and K(V) 7 channels by the non-opioid analgesic flupirtine. Br J Pharmacol. 2012;166(5):1631–1642. - PMC - PubMed
    1. Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. J Neural Transm (Vienna) 1999;106(9–10):857–867. - PubMed
    1. Raffa RB, Pergolizzi JV., Jr The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther. 2012;37(1):4–6. - PubMed
    1. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs. 1993;45(4):548–569. - PubMed
    1. Harish S, Bhuvana K, Bengalorkar GM, Kumar TN. Flupirtine: clinical pharmacology. J Anaesthesiol Clin Pharmacol. 2012;28(2):172–177. - PMC - PubMed

Publication types

Feedback